Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $699000.0.

  • Taysha Gene Therapies' Gains from Investment Securities fell 7217.06% to $699000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.8 million, marking a year-over-year decrease of 267886.0%. This contributed to the annual value of $3.7 million for FY2024, which is 4832.79% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Gains from Investment Securities is $699000.0, which was down 7217.06% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Gains from Investment Securities peaked at $18.6 million during Q1 2022, and registered a low of -$65.7 million during Q4 2023.
  • Moreover, its 4-year median value for Gains from Investment Securities was $2.4 million (2023), whereas its average is -$1.5 million.
  • Per our database at Business Quant, Taysha Gene Therapies' Gains from Investment Securities crashed by 1665869.02% in 2023 and then surged by 129637.83% in 2025.
  • Taysha Gene Therapies' Gains from Investment Securities (Quarter) stood at $397000.0 in 2022, then tumbled by 16658.69% to -$65.7 million in 2023, then surged by 99.89% to -$72000.0 in 2024, then soared by 1070.83% to $699000.0 in 2025.
  • Its last three reported values are $699000.0 in Q3 2025, $3.5 million for Q2 2025, and $4.7 million during Q1 2025.